Giuseppe Lippi, Laura Chiozza, Camilla Mattiuzzi and Mario Plebani
Background: Patient and sample misidentification may cause significant harm or discomfort to the patients, especially when incorrect data is used for performing specific healthcare activities. It is hence obvious that efficient and quality care can only start from accurate patient identification. There are many opportunities for misidentification in healthcare and laboratory medicine, including homonymy, incorrect patient registration, reliance on wrong patient data, mistakes in order entry, collection of biological specimens from wrong patients, inappropriate sample labeling and inaccurate entry or erroneous transmission of test results through the laboratory information system. Many ongoing efforts are made to prevent this important healthcare problem, entailing streamlined strategies for identifying patients throughout the healthcare industry by means of traditional and innovative identifiers, as well as using technologic tools that may enhance both the quality and efficiency of blood tubes labeling. The aim of this article is to provide an overview about the liability of identification errors in healthcare, thus providing a pragmatic approach for diverging the so-called patient identification crisis.
Sylwia Tobólska, Sylwia Terpiłowska, Jerzy Jaroszewski and Andrzej Krzysztof Siwicki
use of mammalian cells in in vitro tests increases the sensitivity for the detection of rodent carcinogens and extends the spectrum of genetic incidences detected. A battery approach is reasonable because no single test is able to detect all genotoxic mechanisms. The general features of a standard test battery are as follows:
1. assessment of mutagenicity in a bacterial reverse gene mutation test by Ames;
2. genotoxicity evaluated in mammalian cells in vitro and/or in vivo by comet and micronuclei assays ( 10 ).
The aim of the presented work was to